

1 The clinical spectrum of COVID-19: A population-based 2 cohort study in Iceland

3 Elias Eythorsson M.D., Ph.D.¹, Dadi Helgason M.D., Ph.D.¹, Ragnar Freyr Ingvarsson
4 M.D.¹, Helgi K Bjornsson M.D.¹, Lovisa Bjork Olafsdottir M.D.¹, Valgerdur Bjarnadottir
5 M.D.¹, Hrafnhildur Linnet Runolfsdottir M.D.¹, Solveig Bjarnadottir B.Sc.^{1,2}, Arnar Snaer
6 Agustsson M.D.¹, Kristin Oskarsdottir M.D.¹, Hrafn Hliddal Thorvaldsson M.D.¹, Gudrun
7 Kristjansdottir B.Sc.^{1,2}, Brynja Armannsdottir M.D., M.P.H.¹, Agnar Bjarnason M.D.,
8 Ph.D.^{1,2}, Birgir Johannsson M.D.¹, Olafur Gudlaugsson M.D.¹, Magnus Gottfredsson
9 M.D., Ph.D.^{1,2}, Martin I Sigurdsson M.D., Ph.D.^{1,2}, Olafur S Indridason M.D., M.H.S.¹,
10 Runolfur Palsson M.D.^{1,2}

11 ¹Landspítali–The National University Hospital of Iceland

12 ²Faculty of Medicine, School of Health Sciences, University of Iceland

13

14 Corresponding author is Runolfur Palsson M.D.

15 Address: Landspítali–The National University Hospital of Iceland, Reykjavik, Iceland

16 Email: runolfur@landspitali.is

17 Telephone: +354-824-5827

18

1 **Key points**

2 **Question:** What is the frequency and progression of various symptoms experienced by
3 patients with COVID-19?

4 **Findings:** In this population-based cohort study that included all SARS-CoV-2-positive
5 patients in Iceland, most patients (67.5%) had mild symptoms throughout their disease
6 course. At the time of diagnosis, 5.3% were asymptomatic, of whom roughly half
7 developed symptoms during follow-up. Common presenting symptoms included myalgia
8 (55%), headache (51%), and non-productive cough (49%). At diagnosis, 13.8%
9 and 22.3% did not meet the Centers for Disease Control and Prevention and World
10 Health Organization case definitions for suspected COVID-19, respectively.

11 **Meaning:** In the setting of broad access to diagnostic testing, the majority of SARS-
12 CoV-2-positive patients were found to have mild symptoms and almost one-fifth did not
13 meet published clinical criteria for RT-PCR testing.

1 **Abstract**

2 **Background:** Previous studies on the epidemiology and clinical characteristics of
3 COVID-19 have generally been limited to hospitalized patients. The aim of this study
4 was to describe the complete clinical spectrum of COVID-19, based on a nationwide
5 cohort with extensive diagnostic testing and a rigorous contact tracing approach.

6 **Methods:** A population-based cohort study examining symptom progression using
7 prospectively recorded data on all individuals with a positive test (RT-PCR) for severe
8 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who were enrolled in a
9 telehealth monitoring service provided to all identified cases in Iceland. Symptoms were
10 systematically monitored from diagnosis to recovery.

11 **Results:** From January 31 to April 30, 2020, a total of 45,105 individuals (12% of the
12 Icelandic population) were tested for SARS-CoV-2, of whom 1797 were positive,
13 yielding a population incidence of 5 per 1000 individuals. The most common presenting
14 symptoms were myalgia (55%), headache (51%), and non-productive cough (49%). At
15 the time of diagnosis, 5.3% of cases reported no symptoms and 3.1% remained
16 asymptomatic during follow-up. In addition, 216 patients (13.8%) and 349 patients
17 (22.3%) did not meet the case definition of the Centers for Disease Control and
18 Prevention and the World Health Organization, respectively. The majority (67.5%) of
19 patients had mild symptoms throughout the course of the disease.

20 **Conclusion:** In the setting of broad access to diagnostic testing, the majority of SARS-
21 CoV-2-positive patients were found to have mild symptoms. Fever and dyspnea were

- 1 less common than previously reported. A substantial proportion of patients did not meet
- 2 recommended case definitions at the time of diagnosis.

1 Introduction

2 On December 31 2019, the first cases of an atypical pneumonia of unidentified etiology
3 were reported in Wuhan, China.¹ One week later, a novel betacoronavirus, later named
4 severe acute respiratory syndrome coronavirus (SARS-CoV-2), was identified as the
5 causative pathogen^{2,3}, and the disease subsequently termed coronavirus disease 2019
6 (COVID-19). The World Health Organization (WHO) declared the COVID-19 outbreak a
7 pandemic on March 11, 2020.⁴

8 COVID-19 has a wide range of clinical manifestations, ranging from an asymptomatic
9 state or mild respiratory symptoms to severe viral pneumonia and acute respiratory
10 distress syndrome.⁵⁻⁷ Previous publications have suggested that approximately 81% of
11 patients have mild symptoms, 14% have severe symptoms, and 5% become critically
12 ill.⁸ Besides respiratory symptoms, dysosmia, dysgeusia, abdominal pain, diarrhea, and
13 rash have been described.^{5,9} Most published studies on the clinical characteristics of
14 COVID-19 have been retrospective^{5,8,10,11} and limited to inpatients^{12,13} and therefore do
15 not capture the full clinical spectrum of the disease.

16 The first case of COVID-19 in Iceland was diagnosed on February 27, 2020.¹⁴ Icelandic
17 health authorities responded immediately by isolating patients and instituting systematic
18 contact tracing and quarantine of exposed individuals.¹⁵ Broad access to diagnostic
19 testing became available in Iceland early in the course of the pandemic, allowing the
20 highest rate of SARS-CoV-2 testing in the world.¹⁶ Approximately one month after the
21 first case was identified, the incidence of undetected cases was found to be only 0.6%
22 using random population screening.¹⁴ All SARS-CoV-2-positive individuals were actively

1 monitored at a newly established COVID-19 outpatient clinic at Landspítali–The
2 National University Hospital (LUH).^{15,17} The contact tracing and containment strategies
3 implemented by the Icelandic authorities rapidly curbed the epidemic, with only 4 new
4 cases diagnosed between May 1 and 15.¹⁴

5 In this paper, we describe the analysis of prospectively collected data on all SARS-CoV-
6 2-positive patients in Iceland and characterize the epidemiology and full clinical
7 spectrum of COVID-19 in a nationwide cohort.

1 **Methods**

2 ***Study population and design***

3 This population-based cohort study included all patients who tested positive for SARS-
4 CoV-2 between February 27 and April 30, 2020, and were actively monitored at LUH.
5 All individuals in Iceland who tested positive for SARS-CoV-2 were immediately
6 contacted, instructed to isolate, and enrolled in a telehealth monitoring service.
7 Monitoring involved frequent telephone interviews by a nurse or physician, through
8 which the patient's clinical status was evaluated. From February 27 to March 16, 2020,
9 the content and documentation of these interviews was at the discretion of the nurse or
10 physician making the call. On March 17, a standardized data entry form was built
11 directly into the national electronic medical record system, facilitating a structured
12 approach to the clinical evaluation of COVID-19 patients. The study was approved by
13 the National Bioethics Committee (VSN-20-078).

14 ***Virological testing***

15 Real-time reverse-transcriptase polymerase chain reaction (RT-PCR) was used for
16 detection of SARS-CoV-2 RNA in nasopharyngeal and oropharyngeal swabs, based on
17 the WHO recommended protocol from Charité, Berlin¹⁸ or using a commercial kit
18 (TaqMan 2019-nCoV Assay from Thermo Fisher Scientific) as previously described.¹⁵
19 Three testing protocols were implemented: targeted testing, open-invitation population
20 screening, and random population screening. Targeted testing was performed at the
21 Department of Clinical Microbiology at LUH, whereas population screening was carried
22 out by deCODE genetics, a biopharmaceutical company based in Reykjavik.¹⁵ Targeted

1 testing began on January 31, 2020, and included clinically suspected cases and
2 individuals at high risk of exposure. Open-invitation population screening began on
3 March 13, 2020, and was available to all Icelandic residents who were not currently
4 quarantined and did not have symptoms that would prompt targeted testing. Finally, a
5 randomly chosen sample of 6782 Icelanders was offered testing via telephone text
6 message on March 31 and April 1, 2020, of whom 2283 were included.

7 ***Data collection***

8 To confirm the completeness of telehealth enrollment, results of all SARS-CoV-2 testing
9 were obtained from databases of LUH and deCODE genetics. Negative samples were
10 used for denominator calculations. Baseline characteristics of SARS-CoV-2-positive
11 patients and longitudinal data on symptom progression were obtained from the
12 standardized data entry forms used by the COVID-19 Clinic. Data on clinical outcomes
13 were extracted from LUH database. Data were linked using government issued national
14 identification numbers. Population demographics were obtained from Statistics Iceland
15 (www.statice.is).

16 ***The telehealth monitoring service***

17 The initial patient interviews were conducted by a physician who informed the patients
18 of the diagnosis, evaluated their health, and instructed them to self-isolate at home. A
19 checklist of 19 specific symptoms was presented to each patient during the initial and all
20 subsequent interviews (Table 1). Patients were asked whether they had experienced
21 any of the 19 symptoms from the time of symptom onset to the time of the interview.

1 Additionally, the patient's baseline characteristics were documented, including past
2 medical history, medication use, and social history.

3 Based on the symptoms documented during the interviews, patients were classified into
4 one of three categories of clinical severity: low severity, defined as mild and improving
5 symptoms; moderate severity, defined as mild dyspnea, cough or fever for less than five
6 days; and high severity, defined as worsening dyspnea, worsening cough, high or
7 persistent fever for five days or longer, or severe fatigue. The frequency of follow-up
8 interviews ranged from daily to every fourth day, depending on clinical severity, age,
9 and underlying conditions. Patients with concerning symptoms were referred for
10 evaluation at the COVID-19 Clinic.

11 Patients were discharged from telehealth monitoring when they met both of the
12 following criteria: 14 days had passed since the diagnosis of COVID-19, and they had
13 been asymptomatic for the past seven consecutive days.

14 ***Case definitions***

15 Patients were considered symptomatic due to COVID-19 using three different
16 definitions: 1) Reporting any of the 19 symptoms; 2) WHO case definition of suspected
17 COVID-19, which included fever and at least one other symptom of acute respiratory
18 infection, e.g. cough or shortness of breath¹⁹; 3) Centers for Disease Control and
19 Prevention (CDC) interim case definition of COVID-19, which included either two of the
20 following symptoms: fever, rigor, myalgia, headache, sore throat, dysosmia or
21 dysgeusia, or one of the following symptoms: cough, shortness of breath or difficulty
22 breathing.²⁰ Patients who did not fulfill these definitions at the time of diagnosis or

1 during follow-up, were determined to be asymptomatic. Otherwise, they were
2 considered presymptomatic at the time of diagnosis.

3 ***Statistical analysis***

4 The incidence of COVID-19 was calculated by age and sex, using both the Icelandic
5 population and all SARS-CoV-2 tested individuals as denominators. Patients were
6 followed until discharge from the telehealth monitoring service, hospital admission,
7 death or end of the study period (May 22, 2020). Patients enrolled prior to the
8 implementation of the standardized data entry form (March 17, 2020) were excluded
9 from the analysis of symptoms and symptom progression.

10 The progression of COVID-19 symptoms was analyzed using parametric cure-mixture
11 models and logistic regression. The time frame used in the analyses was days from
12 symptom onset to discharge from telehealth monitoring. The data were interval
13 censored due to the intermittent schedule of the interviews. To account for this, the
14 cumulative incidence of symptom occurrence was estimated with the non-parametric
15 Turnbull estimator and a parametric cure-mixture model using the log-logistic
16 distribution. The proportion of patients experiencing a specific symptom per day was
17 estimated employing logistic regression that allowed for non-linear effects using a three-
18 knot restricted cubic spline. Missing information between interviews was addressed by
19 multiple imputation using chained equations, performed by additive regression,
20 bootstrapping and predictive mean matching procedure.²¹ The number of imputations
21 equaled the highest proportion of missing data for any variable, multiplied by 100. The
22 added uncertainty due to imputation was fully accounted for in the logistic regression

- 1 models. The result was compared to a complete-case analysis and naive up-down filling
- 2 procedure.
- 3 All statistical analyses were performed in R version 3.6.3.

1 **Results**

2 ***Demographics and clinical characteristics***

3 A total of 45,105 individuals (12% of the Icelandic population) underwent 47,800 tests
4 for SARS-CoV-2 from January 31 to April 30, 2020. Of those, 18,023 (37.7%) were
5 carried out as part of targeted testing and 29,785 (62.3%) were done as part of
6 population screening. Altogether, 1797 patients experienced 1911 positive tests. The
7 population incidence of COVID-19 was 4.9 cases per 1000 individuals, and 40.0 per
8 1000 tests performed were positive. This rate differed between targeted testing (1703 of
9 18,023 samples positive or 94.4 per 1000 tests performed) and population screening
10 (208 of 29,785 samples positive or 7.0 per 1000 tests performed). Among tested
11 individuals, the proportion of females (58%) was higher than in the general population
12 (49%). However, the sex distribution was equal among patients who tested positive
13 (Supplemental Figure 1).

14 All patients who tested positive were enrolled in telehealth monitoring or admitted to
15 hospital, with no exceptions. The clinical progression from symptom onset for the 1797
16 positive individuals is shown in Figure 1. Thirty-two of those patients were diagnosed
17 after being admitted to hospital of whom one was diagnosed post-mortem (Figure 2). In
18 total, 101 (5.7%) patients were hospitalized, 27 (1.5%) were admitted to intensive care
19 and 16 (0.9%) required mechanical ventilation. The median length of hospital stay was
20 8 days (IQR, 3.5-19) and 10 (0.6%) patients died.

1 ***Symptoms at diagnosis***

2 Of the 1797 SARS-CoV-2-positive patients, 41.5% had experienced fever at diagnosis.
3 Other symptoms such as cough (59.2%), dyspnea (30.4%), and gastrointestinal
4 symptoms (32.3%) were also commonly reported. A total of 100 (5.7%) patients
5 reported no symptoms at diagnosis, which was more common among those who were
6 diagnosed through population screening (22.0%) as compared to targeted testing
7 (5.5%). The total number of documented symptoms at diagnosis was lower among
8 patients diagnosed before the implementation of standardized data collection compared
9 to those diagnosed following the implementation (Supplemental Figure 2). Therefore,
10 this latter group was used to study the symptom development and progression in detail
11 (Figure 2).

12 Of the 1564 (87%) patients who were followed using the standardized data entry form,
13 791 (51%) were female and the median age was 40 years (IQR, 26-53; range, 0-103).
14 The distribution of age and sex is shown in Supplemental Figure 1. Among these
15 patients, 1055 (67.5%) were classified as having low disease severity throughout their
16 follow-up, 55 (3.5%) were admitted to hospital and 13 (0.8%) required intensive care,
17 six (0.4%) of whom received mechanical ventilation. Two (0.1%) of these patients died.
18 The patients were followed for a median of 15 days (IQR, 14-18) and contributed 69.2
19 person-years of follow-up time. A total of 1509 patients completed telehealth follow-up
20 from diagnosis until discharge-. The observation time of the remaining 55 patients who
21 were hospitalized was censored at the time of admission, after a median follow-up of 4
22 days (IQR, 2.5-8). Demographic information by subgroup of included and excluded
23 patients is presented in Supplemental Table 1.

1 Of the 1564 patients with standardized symptom documentation, 42.7% had
2 experienced fever at diagnosis. Cough (60.1%), dyspnea (31.7%), and gastrointestinal
3 symptoms (35.7%) were also commonly reported. Eighty-three (5.3%) patients reported
4 no symptoms at diagnosis, which was more commonly observed among those
5 diagnosed through population screening (24.5%) as compared with patients diagnosed
6 by targeted testing (3.2%). Of the patients who were asymptomatic at diagnosis, 49
7 (59.0%) remained asymptomatic throughout their telehealth monitoring, while the
8 remaining 34 (41.0%) patients developed symptoms after a median of 3 days (IQR, 3-
9 4.75).

10 Using the CDC case definition, 216 (13.8%) patients would be categorized as not
11 having symptoms consistent with COVID-19 at the time of diagnosis. This was more
12 common among patients diagnosed through population screening (40.6%) than by
13 targeted testing (10.9%). Seventy-two (4.6%) of those patients developed symptoms
14 compatible with the CDC case definition at a median of 5 days (IQR, 3-6) from
15 diagnosis, whereas the other 144 (9.2%) never met the CDC criteria. Similarly, 349
16 (22.3%) patients did not fulfill the WHO case definition at the time of diagnosis, a finding
17 that was more commonly observed among patients diagnosed through population
18 screening (45.8%) than by targeted testing (19.7%). The WHO criteria were later met by
19 115 (7.4%) patients at a median of 4 days (IQR, 3-6) from diagnosis, while the
20 remaining 234 (15.0%) patients never fulfilled the criteria.

21 The cumulative incidence and proportion of patients meeting CDC and WHO criteria by
22 number of days from symptom onset is shown in Supplemental figure 3. Among the 216
23 individuals who did not meet CDC criteria at diagnosis, four (1.9%) were hospitalized

1 later in the course of their disease, and one required mechanical ventilation. Similarly,
2 four (1.1%) of the 349 individuals who did not fulfill the WHO criteria at diagnosis were
3 admitted to hospital for illness related to COVID-19, two of whom required intensive
4 care.

5 ***Symptom development and progression assessed by multiple imputation***

6 The median time from symptom onset until RT-PCR diagnosis and enrollment interview
7 was four days (IQR, 2-7) and a median of six (IQR, 4-8) interviews were conducted per
8 patient during telehealth monitoring. The median time between interviews was two days
9 (IQR, 1-3). No data were missing for the days during which interviews occurred.
10 Symptoms occurring on days during which interviews were not conducted were imputed,
11 and the imputation procedure was repeated 92 times. The proportion of patients with
12 missing information on symptoms was highest during the first days following symptom
13 onset (Supplemental Table 2). The proportion of patients experiencing specific
14 symptoms per day from symptom onset was calculated using multiple imputation logistic
15 regression, which produced acceptable results as compared with complete-case
16 analysis and a naïve up-down filling procedure (Supplemental Figures 4-7).

17 ***Symptoms at disease onset***

18 As shown in Table 1, the most common symptoms at the onset of COVID-19 were
19 myalgia, headache, and non-productive cough, observed in 51% (95%CI, 47%-55%),
20 49% (95%CI, 45%-53%), and 55% (95%CI, 51%-60%), respectively. However, 82%
21 (95%CI, 80%-85%) of patients experienced at least one generalized symptom and 63%
22 (95%CI, 59%-67%) at least one upper respiratory symptom. Compared with patients

1 diagnosed by targeted testing, those diagnosed through population screening were less
2 likely to have experienced cardinal symptoms of COVID-19 at disease onset, including
3 fever (30% vs. 43%), cough (47% vs. 59%), dyspnea (18% vs. 26%) and
4 gastrointestinal symptoms (23% vs. 31%). Other symptoms according to testing
5 protocol are shown in Supplemental Figures 8-11.

6 The proportion of patients experiencing specific symptoms by sex and age group is
7 displayed in Supplemental Figures 12-15. The initial presentation of COVID-19 varied
8 only slightly between the sexes. The proportion experiencing fever or gastrointestinal
9 symptoms at onset was similar between age groups, but cough and dyspnea were more
10 common among older individuals (Supplemental Figure 14).

11 Differences in symptoms at onset between hospitalized and non-hospitalized patients
12 are shown in Supplementary Figures 16-19. Several symptoms at disease onset were
13 more common among patients who were later admitted to hospital, including
14 generalized symptoms (94% vs 82%), lower respiratory symptoms (71% vs 62%) and
15 gastrointestinal symptoms (48% vs 29%). However, the proportion of patients who
16 experienced upper respiratory symptoms was lower, 48% compared with 64% of those
17 who were never hospitalized.

18 ***Progression of symptoms***

19 By day 21 from disease onset, the most commonly experienced symptoms were
20 lethargy, headache, and productive or non-productive cough, noted in 74% (95%CI,
21 72%-77%), 73% (95%CI, 70%-75%) 73% (95%CI 70%-75%), respectively. Overall,
22 93% (95%CI, 91%-94%) had experienced at least one generalized symptom, 87%

1 (95%CI, 85%-89%) at least one upper respiratory symptom, and 80% (95%CI, 78%-
2 82%) at least one lower respiratory symptom. The cumulative incidence of fever,
3 dyspnea, and gastrointestinal symptoms were 49%, 52%, and 53%, respectively (Figure
4 3). The proportion of patients experiencing each symptom by days from symptom onset
5 is shown in Figure 4. Of the 741 patients who experienced fever at any time during the
6 course of the disease, 630 (85%) had done so by day 3. Furthermore, 902 of 1140
7 patients (79%) had developed cough by day 3, 427 of 826 (52%) had developed
8 dyspnea and 485 of 788 (62%) had developed any gastrointestinal symptom by day 3
9 (Figure 3). These proportions were comparable for both sexes and all age groups
10 (Supplemental Figures 20-31).

11 Of the 19 symptoms, only dysosmia and dysgeusia were more common later in the
12 disease course than at symptom onset. Both symptoms peaked on day eight from
13 diagnosis. The trend was most pronounced among patients aged 25 to 55 years and
14 was more marked among females (Supplemental Figure 13). Other symptoms attributed
15 to COVID-19 were most prevalent during the onset of the disease. No symptom
16 exhibited a bimodal pattern (Supplemental Figures 12-15). The cumulative incidence of
17 each specific symptom was lower among patients diagnosed through population
18 screening compared to targeted testing, except for rhinorrhea and vomiting
19 (Supplemental Figures 32-35). By day 21, a large proportion of patients who were ever
20 admitted to hospital for COVID-19 had experienced fever, dyspnea and and
21 gastrointestinal symptoms, or 91% (95%CI, 71%-95%), 83% (95%CI, 64%-91%), and
22 84% (95%CI, 66%-91%), respectively (Supplemental Figures 36-39).

1 Discussion

2 In this study we present the clinical characteristics of COVID-19 in a national
3 population-based cohort. Due to aggressive contact tracing and widespread virological
4 testing it is likely that the cohort includes the majority of symptomatic cases in the
5 population. This assumption is supported by the low prevalence of the disease detected
6 by random population screening (0.6%).¹⁵ Our prospectively collected data regarding
7 symptoms and disease progression among patients who tested positive for SARS-CoV-
8 2 in Iceland revealed that 49% of patients experienced fever, 73% cough, and 52%
9 dyspnea. At the time of diagnosis, 5% were completely asymptomatic, 13% did not
10 meet the CDC case definition, and 22% did not fulfill the WHO criteria.

11 The comprehensive, nationwide characterization of COVID-19 symptoms was facilitated
12 by broad access to diagnostic testing in Iceland. The Icelandic healthcare system is a
13 single-payer system with a universal government-run health insurance provider. The
14 SARS-CoV-2 RT-PCR test was free of charge for both targeted testing and population
15 screening, resulting in over 12% of the population tested, which was higher than in any
16 other country during the study period.¹⁶ As a result, we were able to describe the true
17 spectrum of COVID-19, while previous studies were largely based on hospitalized
18 cohorts or cases identified in the setting of more restrictive testing.^{6,12,22} Furthermore,
19 subgroup analysis allowed us to quantify the degree by which cohorts with only
20 hospitalized patients might overestimate the presence of specific symptoms, for
21 instance fever, which was considerably more common at symptom onset in patients

1 who were later admitted to hospital (74%) than in patients who never were hospitalized
2 (40%).

3 The proportion of patients with COVID-19 who were completely asymptomatic has been
4 a focus of interest during the pandemic with implications for the risk of disease
5 dissemination. A recent report from Iceland examining an overlapping cohort suggested
6 that 43% of patients were asymptomatic at the time of sampling.¹⁵ This estimate was
7 derived from 43 out of 100 RT-PCR positive cases reporting no symptoms at the time of
8 diagnosis among 13,080 participants in a population screening program, which included
9 both open-invitation and random invitation screening. Follow-up information on the
10 patients' symptoms was not available to the authors¹⁵, possibly resulting in an
11 overestimation of asymptomatic individuals. In the current study, 83 patients reported no
12 symptoms at the time of diagnosis, approximately half of whom developed symptoms in
13 the ensuing days. Thus only 3.1% of diagnosed cases remained completely symptom-
14 free during follow-up. However, as some degree of suspicion of COVID-19 was needed
15 to prompt an individual to be tested, symptomatic patients are likely to be
16 overrepresented in our sample. Estimating the true proportion of SARS-CoV-2-positive
17 patients who never develop symptoms is difficult, as asymptomatic patients are unlikely
18 to be diagnosed outside of random population screening, and differentiating pre-
19 symptomatic from asymptomatic patients requires longitudinal follow-up. Gudbjartsson
20 et al. found that 13 out of 2283 randomly sampled Icelanders were SARS-CoV-2-
21 positive, of which 7 (53.8%) reported no symptoms at the time of diagnosis. We have
22 shown that 59.0% of patients who are symptom free at diagnosis, never develop

1 symptoms. Based on these observations, the rough estimate of the proportion of truly
2 asymptomatic SARS-CoV-2-positive Icelanders is approximately 30%.

3 Of symptomatic patients, most experienced only minor symptoms. Only 22% of patients
4 developed moderate symptoms, 8% severe symptoms, and 3.5% were hospitalized.

5 The standardized prospective recording of clinical symptoms made it possible to
6 evaluate the sensitivity of the widely used CDC²⁰ and WHO¹⁹ case definitions for the
7 diagnosis of COVID-19 throughout the course of the disease. By applying these
8 definitions, we demonstrate that a substantial number of cases would have been
9 missed; approximately 9% by the CDC criteria and 15% by the WHO criteria. The
10 identification of additional 4% and 7% of cases would have been delayed by a median
11 of 5 and 4 days, respectively. These are concerning results with immediate implications
12 for current efforts to curtail the pandemic. Our data show that most patients have mild
13 symptoms that may not have prompted the consideration of COVID-19 by either
14 patients or health care providers in more resource-limited settings, and indicates a need
15 for revising and widening the CDC and WHO case definitions to increase their
16 sensitivity.

17 Symptoms observed among patients with mild forms of COVID-19 have previously been
18 examined in a multicenter European study of 1420 RT-PCR positive patients who
19 answered a questionnaire.¹⁰ Severely ill patients were excluded and the remaining
20 cohort was predominantly female (68%), young (94% were <60 years of age), and
21 biased towards healthcare workers (31% of the group).¹⁰ While these results are not
22 easily generalizable to the entire population, the investigators found that only 7% of
23 patients required hospitalization¹⁰ compared to 3.5% in the present study. Headache,

1 loss of smell, and nasal obstruction were the most common symptoms identified.¹⁰

2 Although these symptoms were also frequently identified in our cohort, we found cough
3 and myalgias to be more common. The predominance of loss of smell identified in the
4 aforementioned study agrees with our observation that olfactory symptoms are most
5 common in younger age groups.¹⁰

6 We found that slightly less than 50% of patients developed fever during the course of
7 the disease, already present in 85% of those by day 3. This is consistent with the study
8 by Lechien et al. in which fever $\geq 38.0^{\circ}\text{C}$ was reported in 45.4% of cases¹⁰, while it is
9 higher than was reported by Guan et al. (21.7%)⁵ and Goyal et al. (25%)¹². A meta-
10 analysis by Sun et al. found that 89% of COVID-19 patients had a fever $\geq 37.3^{\circ}\text{C}$ ⁶, but
11 this definition of fever is rarely used in clinical practice. Over the follow-up period, 70%
12 of patients experienced cough which is consistent with the findings of Lechien et al. who
13 observed cough in 63% of cases¹⁰. In total, 52% of patients reported any dyspnea and
14 only 13% reported dyspnea at rest during the disease. The reported incidence of
15 dyspnea ranges from 22-49%^{7,10,23} but most previous studies do not differentiate
16 between dyspnea at rest and on exertion. Gastrointestinal symptoms were common,
17 reported by almost half of patients at some point during the first 14 days. Abdominal
18 pain (22%) and diarrhea (28%) were frequent as in previous studies.^{12,24} Interestingly,
19 although one-fourth of patients experienced nausea, vomiting was rare.

20 Our findings indicate a lower rate of hospital admissions and mortality in Iceland
21 compared with many other countries. The reasons for these disparate outcomes are
22 likely multifactorial. Iceland has a relatively young population, with 85.8% younger than

1 65 years, compared with 77.1% in Italy, 80.6% in Spain, 81.6% in the United Kingdom,
2 and 83.5% in the USA.^{25,26} This, in addition to a strong emphasis on limiting exposure of
3 elderly and multimorbid individuals, resulted in a low median age of confirmed COVID-
4 19 cases of 40 years (IQR, 26-53) in Iceland compared to 51 years (IQR, 36-65) among
5 all cases reported to the WHO²⁷ and 48 years (IQR, 33-63) in the USA.²⁸ Different rates
6 of other recognized risk factors for worse outcomes in COVID-19 are unlikely to explain
7 this difference as they have a similar distribution in Iceland as in other countries, for
8 instance 28.8% of Icelandic adults have hypertension²⁹ and 27% are obese.³⁰

9 This study does have some limitations. In order to accurately describe symptom
10 progression, cases diagnosed before the implementation of the standardized clinical
11 data entry form were excluded from the analysis of symptom development, representing
12 11% of all SARS-CoV-2-positive cases in Iceland. The date of implementation of the
13 standardized data entry form was not influenced by the clinical characteristics of the
14 patients being diagnosed, and therefore should not introduce bias. Furthermore, the
15 demographics and clinical characteristics of excluded cases were largely comparable to
16 those that were included in the study. Another limitation is that daily standardized
17 documentation of symptoms was not available during hospital admission. This could
18 conceivably lead to an underestimation of severe symptoms such as dyspnea.

19 However, only 3.5% of the included patients were hospitalized, and symptoms prior to
20 hospitalization were included in the analysis. It is important to note that the data were
21 based on self-reported symptoms via telephone calls. This shortcoming is mitigated by
22 the fact that experienced nurses and physicians conducted the interviews. A principal

1 strength of the study is its population-based approach, which included all confirmed
2 cases in the country during the study period, regardless of their need for medical care.

3 ***Conclusion***

4 This study describes the symptomatology and clinical severity of the initial phase of
5 COVID-19 in Iceland. The incidence of COVID-19 was high due to extensive testing of
6 both symptomatic and asymptomatic individuals, while disease severity was lower than
7 previously reported. Symptoms such as fever and dyspnea were less frequent than has
8 been observed in earlier studies. Our findings suggest that both the CDC and WHO
9 case definitions of COVID-19 lack sensitivity and miss a substantial proportion of
10 patients, including cases who later develop severe disease.

1 References

2

3 1. World Health Organization. Pneumonia of unknown cause – China.

4 [https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-](https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/)
5 [china/en/](https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/). Accessed May 18, 2020.

6 2. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new
7 coronavirus of probable bat origin. *Nature*. 2020;579(7798):270-273.

8 3. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with
9 pneumonia in China, 2019. *N Engl J Med*'. 2020;382(8):727-733.

10 4. World Health Organization. Coronavirus disease 2019 (COVID-19): situation
11 report — 51. [https://www.who.int/docs/default-source/coronaviruse/situation-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf)
12 [reports/20200311-sitrep-51-covid-19.pdf](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf). Accessed May 18, 2020.

13 5. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019
14 in China. *N Engl J Med*. 2020;382(18):1708-1720.

15 6. Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized
16 patients with SARS-CoV-2 infection: A single arm meta-analysis. *J Med Virol*.
17 2020.

18 7. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, et al. Clinical,
19 laboratory and imaging features of COVID-19: A systematic review and meta-
20 analysis. *Travel Med Infect Dis*. 2020;34:101623.

21 8. Wu Z, McGoogan JM. Characteristics of and important lessons from the
22 coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of

- 1 72314 cases from the Chinese center for disease control and prevention. *JAMA*.
2 2020.
- 3 9. Tian S, Hu N, Lou J, et al. Characteristics of COVID-19 infection in Beijing. *J*
4 *Infection*. 2020;80(4):401-406.
- 5 10. Lechien JR, Chiesa-Estomba CM, Place S, et al. Clinical and epidemiological
6 characteristics of 1,420 European patients with mild-to-moderate coronavirus
7 disease 2019. *J Intern Med*. 2020.
- 8 11. Early epidemiological and clinical characteristics of 28 cases of coronavirus
9 disease in South Korea. *Osong Public Health Res Perspect*. 2020;11(1):8-14.
- 10 12. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New
11 York City. *N Engl J Med*. 2020.
- 12 13. Wu J, Liu J, Zhao X, et al. Clinical characteristics of imported cases of COVID-19
13 in Jiangsu Province: A multicenter descriptive study. *Clin Infect Dis*. 2020.
- 14 14. The Directorate of Health in Iceland and The Department of Civil Protection and
15 Emergency Management. Covid-19 in Iceland - statistics.
16 <https://www.covid.is/data>. Accessed May 18, 2020.
- 17 15. Gudbjartsson DF, Helgason A, Jonsson H, et al. Spread of SARS-CoV-2 in the
18 Icelandic population. *N Engl J Med*. 2020.
- 19 16. Joe Hasell, Esteban Ortiz-Ospina, Edouard Mathieu et al. Daily COVID-19 tests
20 per thousand people. [https://ourworldindata.org/grapher/full-list-daily-covid-19-](https://ourworldindata.org/grapher/full-list-daily-covid-19-tests-per-thousand?country=ECU+IND+IDN+SEN+KOR+USA+LTU+NZL+ISL)
21 tests-per-thousand?country=ECU+IND+IDN+SEN+KOR+USA+LTU+NZL+ISL.
22 Accessed May 18, 2020.

- 1 17. Helgason D, Eythorsson E, Olafsdottir LB, et al. Beating the odds with systematic
2 individualized care. Nationwide prospective follow-up of all patients with COVID-
3 19 in Iceland. *J Intern Med*. 2020.
- 4 18. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus
5 (2019-nCoV) by real-time RT-PCR. *Euro surveillance : bulletin Europeen sur les*
6 *maladies transmissibles = European communicable disease bulletin*. 2020;25(3).
- 7 19. World Health Organization. Global surveillance for human infection with
8 coronavirus disease (COVID-19). 2020; [https://www.who.int/publications-](https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov))
9 [detail/global-surveillance-for-human-infection-with-novel-coronavirus-\(2019-](https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov))
10 [ncov\)](https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)). Accessed May 18, 2020.
- 11 20. Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-
12 19) 2020 interim case definition, Approved April 5, 2020.
13 [https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-](https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/)
14 [definition/2020/](https://wwwn.cdc.gov/nndss/conditions/coronavirus-disease-2019-covid-19/case-definition/2020/). Accessed May 18, 2020.
- 15 21. *Hmisc: Harrell miscellaneous. R package version 4.4-0*. [computer program].
16 2020.
- 17 22. Colaneri M, Sacchi P, Zuccaro V, et al. Clinical characteristics of coronavirus
18 disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy,
19 21 to 28 February 2020. *Euro Surveill*. 2020;25(16).
- 20 23. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics,
21 discharge rate, and fatality rate of meta-analysis. *J Med Virol*. 2020.
- 22 24. Nobel YR, Phipps M, Zucker J, et al. Gastrointestinal symptoms and COVID-19:
23 Case-control study from the United States. *Gastroenterology*. 2020.

- 1 25. United States Census Bureau. National population by characteristics: 2010-2019.
2 [https://www.census.gov/data/tables/time-series/demo/popest/2010s-national-
4 detail.html - par textimage 1537638156](https://www.census.gov/data/tables/time-series/demo/popest/2010s-national-
3 detail.html - par textimage 1537638156). Accessed June 28, 2020.
- 4 26. Eurostat. Population by age group.
5 <https://ec.europa.eu/eurostat/databrowser/view/tps00010/default/table?lang=en>.
6 Accessed June 28, 2020.
- 7 27. World Health Organization. Coronavirus disease 2019 (COVID-19): Situation
8 Report – 89. [https://www.who.int/docs/default-source/coronaviruse/situation-
10 reports/20200418-sitrep-89-covid-19.pdf?sfvrsn=3643dd38_2](https://www.who.int/docs/default-source/coronaviruse/situation-
9 reports/20200418-sitrep-89-covid-19.pdf?sfvrsn=3643dd38_2). Accessed June
11 28, 2020.
- 11 28. Stokes EK, Zambrano LD, Anderson KN, et al. Coronavirus disease 2019 case
12 surveillance - United States, January 22-May 30, 2020. *MMWR Morb Mortal*
13 *Wkly Rep.* 2020;69(24):759-765.
- 14 29. European Society of Cardiology. Country report Iceland - December 2013.
15 [https://www.escardio.org/static_file/Escardio/Subspecialty/EACPR/iceland-
17 country-report.pdf](https://www.escardio.org/static_file/Escardio/Subspecialty/EACPR/iceland-
16 country-report.pdf). Accessed June 28, 2020.
- 17 30. OECD/European Observatory on Health Systems and Policies. Iceland:
18 country health profile 2019, state of health in the EU.
19 https://ec.europa.eu/health/sites/health/files/state/docs/2019_chp_is_english.pdf

1 Tables

2 **Table 1.** Proportion of SARS-CoV-2-positive patients who experienced specific
 3 symptoms and symptom constellations on days 1, 3, 7, and 14 from symptom onset.
 4 The cumulative incidence of the specific symptoms by day 14 is shown in the last
 5 column. All values are reported as percentages with 95% confidence intervals (CI).

Constellation of symptoms	Specific symptoms	Proportion of patients experiencing a symptom per day (%; 95%CI)				Cumulative incidence by day 14 (%)
		Symptom onset	Day 3	Day 7	Day 14	
Generalized		82 (80-85)	78 (75-80)	65 (64-67)	41 (40-42)	93 (91-94)
-	Fever ≥38°C	42 (36-48)	33 (29-37)	18 (17-20)	6.6 (5.7-7.6)	47 (45-50)
-	Rigor, chills	32 (27-38)	24 (21-28)	13 (12-14)	4.9 (4.3-5.4)	43 (40-45)

-	Headache	51 (47-56)	46 (42-49)	35 (34-37)	21 (20-22)	73 (70-75)
-	Myalgia	55 (51-60)	45 (42-49)	27 (26-29)	10 (10-11)	62 (59-64)
-	Lethargy	38 (34-42)	38 (34-41)	36 (35-38)	27 (26-29)	74 (72-77)
-	Loss of appetite	24 (20-28)	23 (20-26)	20 (19-22)	11 (11-12)	46 (43-49)
Upper respiratory		63 (59-67)	60 (57-63)	54 (53-56)	37 (36-38)	87 (85-89)
-	Rhinorrhea	33 (28-38)	28 (26-31)	21 (20-22)	12 (11-13)	55 (53-58)
-	Sore throat	33 (29-38)	27 (25-30)	18 (17-19)	10 (9-11)	45 (43-48)

-	Dysosmia	21 (18-25)	24 (21-26)	28 (27-29)	24 (22-25)	56 (54-59)
-	Dysgeusia	24 (21-28)	26 (24-29)	30 (29-32)	24 (23-25)	58 (55-60)
Lower respiratory		62 (58-65)	60 (58-63)	56 (55-58)	43 (42-45)	80 (78-82)
-	Non-productive cough	49 (45-53)	45 (42-48)	37 (36-39)	24 (23-26)	66 (63-68)
-	Productive cough	13 (11-16)	14 (12-17)	16 (15-17)	15 (14-16)	39 (37-42)
-	Any dyspnea	25 (22-29)	26 (24-29)	28 (26-29)	22 (21-23)	52 (50-54)
-	Dyspnea at rest	5.0 (3.8-6.7)	5.0 (4.0-6.2)	4.8 (4.2-5.5)	3.7 (3.3-4.2)	16 (14-18)

Gastro-intestinal		30 (26-35)	27 (25-30)	22 (20-23)	11 (10-12)	50 (47-52)
-	Nausea	13 (10-17)	12 (10-14)	10 (9-11)	4.9 (4.4-5.5)	26 (24-28)
-	Vomiting	3.3 (1.9-5.4)	2.6 (1.7-3.9)	1.6 (1.1-2.2)	0.7 (0.4-1.0)	4.9 (3.9-6.1)
-	Abdominal pain	11 (9-14)	9.3 (7.9-11)	6.4 (5.7-7.1)	3.7 (3.3-4.2)	24 (22-26)
-	Diarrhea	14 (11-18)	13 (11-15)	10 (9.3-11)	6.0 (5.5-6.6)	29 (27-32)

1

2

3

1 Figures

2 **Figure 1.** Changes in severity of symptoms from onset to end of follow-up among
3 patients with COVID-19. The category “not yet diagnosed” comprises patients yet to be
4 enrolled in telehealth monitoring, and their clinical severity had therefore not been
5 evaluated. The severity of disease was categorized as low (mild and improving
6 symptoms), moderate (mild dyspnea, cough or fever for less than 5 days), and high
7 (worsening dyspnea, worsening cough, high or persistent fever for 5 days or longer, or
8 severe fatigue). The top panel includes all patients. The other panels show subsets of
9 patients by age group; 0-9, 10-19, 20-39, 40-64, and 65 years of age and older.

10 **Figure 2.** Flow-chart describing the derivation of the study cohort.

11 **Figure 3.** Cumulative incidence of specific symptoms experienced by SARS-CoV-2-
12 positive patients by days from symptom onset. The non-parametric Turnbull estimate of
13 the cumulative incidence is depicted in black points and the parametric cure-mixture
14 estimate is illustrated with a black line with the 95% confidence interval shown as a
15 shaded grey area.

16 **Figure 4.** Proportion of SARS-CoV-2-positive patients who experienced specific
17 symptoms by days from symptom onset. The logistic regression estimate of the
18 proportion is illustrated with a black line and the 95% confidence interval shown as a
19 shaded grey area.


20


1 **Authors' contributions**

- 2 Elias Eythorsson - Conception and design, acquisition of data,
3 analysis and interpretation of data and drafting of the manuscript.
4 Dadi Helgason - Conception and design, acquisition of data, interpretation of data and drafting
5 of the manuscript
6 Ragnar Freyr Ingvarsson - Conception and design, and drafting of the manuscript
7 Helgi K Bjornsson - Conception and design, acquisition of data and drafting of the manuscript
8 Lovisa Bjork Olafsdottir - Conception and design, acquisition of data and drafting of the
9 manuscript
10 Valgerdur Bjarnadottir - Acquisition of data and revision of manuscript
11 Hrafnhildur Linnét Runolfsdottir - Acquisition of data and revision of manuscript
12 Solveig Bjarnadottir - Acquisition of data and revision of manuscript
13 Arnar Snaer Agustsson - Acquisition of data and revision of manuscript
14 Kristin Oskarsdottir - Acquisition of data and revision of manuscript
15 Hrafn Hliddal Thorvaldsson - Acquisition of data and revision of manuscript
16 Gudrun Kristjansdottir - Acquisition of data and revision of manuscript
17 Brynja Armannsdottir - Conception and design and revision of manuscript
18 Agnar Bjarnason - Conception and design and drafting of the manuscript
19 Birgir Johannsson - Conception and design and revision of manuscript
20 Olafur Gudlaugsson - Conception and design and revision of manuscript
21 Magnus Gottfredsson - Conception and design and revision of manuscript
22 Martin I Sigurdsson - Conception and design, interpretation of data and revision of manuscript
23 Olafur S Indridason - Conception and design, interpretation of data and revision of manuscript
24 Runolfur Palsson - Conception and design, interpretation of data and revision of manuscript
25
26 All authors gave final approval of the submitted manuscript
27
28


29 **Conflict of interest statements**

- 30 No authors have declared any conflict of interests







Fever




Cough




Dyspnea




Gastrointestinal symptoms




Fever



Cough



Dyspnea



Gastrointestinal symptoms

